The global Rotavirus Vaccines market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 1534% of severe diarrhea in the developing world and 3796% of severe diarrhea in the developed world. The vaccines decrease the risk of death among young children due to diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized.

The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where the disease is common. This should be done along with promoting breastfeeding, handwashing, clean water and good sanitation. It is given by mouth and requires two or three doses. It should be given starting around six weeks of age.

The vaccines are safe. This includes their use in people with HIV/AIDS. An earlier vaccine that is no longer used was linked to intussusception, but the current versions are not clearly linked. Due to a potential risk they are not recommended in babies who have had intussusception. The vaccines are made from weakened rotavirus.

The vaccine first became available in the United States in 2006. It is on the World Health Organizations List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between US$6.96 and $20.66 per dose as of 2014.In the United States it is more than US$200. As of 2013 there are two types of vaccine available globally, Rotarix and RotaTeq. Others are used in some countries.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Infinity Market Research newest research report, the Rotavirus Vaccines Industry Forecast looks at past sales and reviews total world Rotavirus Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected Rotavirus Vaccines sales for 2025 through 2031. With Rotavirus Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Rotavirus Vaccines industry.

This Insight Report provides a comprehensive analysis of the global Rotavirus Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Rotavirus Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Rotavirus Vaccines market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Rotavirus Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Rotavirus Vaccines.

This report presents a comprehensive overview, market shares, and growth opportunities of Rotavirus Vaccines market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Rotarix
    RotaTeq
    Rotavac
    Rotavin-M1
    Lanzhou lamb
    Others

Segmentation by Application:

    Adult
    Pediatric

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Bharat Biotech
    Merck & Co., Inc
    GlaxoSmithKline plc
    Lanzhou Institute of Biological
    Bharat Biotech International Limited

Key Questions Addressed in this Report

What is the 10-year outlook for the global Rotavirus Vaccines market?
What factors are driving Rotavirus Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Rotavirus Vaccines market opportunities vary by end market size?
How does Rotavirus Vaccines break out by Type, by Application?